The KEYNOTE-o42 trial demonstrated that taking Keytruda was more effective in treating lung cancer than chemotherapy, and further findings could mean that patients can skip chemo treatment altogether. The recent stock gain represents almost $5.75 billion in market value.
Keytruda earned Merck more than $3.8 billion in sales in 2017.
More articles on business:
Boeing swipes $12B American Airlines order from rival Airbus
Viacom asks CBS to increase merger offer by $2.8B
Facebook suspends 2 more analytics companies in wake of scandal
